{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T17:00:53Z","timestamp":1746723653818,"version":"3.37.3"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T00:00:00Z","timestamp":1652227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T00:00:00Z","timestamp":1652227200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000027","name":"U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["AA028292","AA028292"],"award-info":[{"award-number":["AA028292","AA028292"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["K23 DA038726","R01 DA022520","R01 DA027494","DA022520","DA027494","DA046345","DA038726"],"award-info":[{"award-number":["K23 DA038726","R01 DA022520","R01 DA027494","DA022520","DA027494","DA046345","DA038726"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse"},{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["R01 MH086858","R21 MH069612","MH069612"],"award-info":[{"award-number":["R01 MH086858","R21 MH069612","MH069612"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse"},{"DOI":"10.13039\/100008460","name":"U.S. Department of Health & Human Services | NIH | National Center for Complementary and Integrative Health","doi-asserted-by":"publisher","award":["R01 AT001415","AT001415"],"award-info":[{"award-number":["R01 AT001415","AT001415"]}],"id":[{"id":"10.13039\/100008460","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health"},{"name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse"},{"DOI":"10.13039\/100006545","name":"U.S. Department of Health & Human Services | NIH | National Institute on Minority Health and Health Disparities","doi-asserted-by":"publisher","award":["MH086858"],"award-info":[{"award-number":["MH086858"]}],"id":[{"id":"10.13039\/100006545","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse"},{"name":"U.S. Department of Health & Human Services | NIH | National Center for Complementary and Integrative Health"},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health"},{"name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse"},{"name":"U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism"},{"name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse"},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["I01 CX001734","VISN 4 MIRECC"],"award-info":[{"award-number":["I01 CX001734","VISN 4 MIRECC"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol."],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1038\/s41386-022-01325-1","type":"journal-article","created":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T10:07:53Z","timestamp":1652263673000},"page":"1784-1790","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Unique and joint associations of polygenic risk for major depression and opioid use disorder with endogenous opioid system function"],"prefix":"10.1038","volume":"47","author":[{"given":"Tiffany","family":"Love","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrey A.","family":"Shabalin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8820-2659","authenticated-orcid":false,"given":"Rachel L.","family":"Kember","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna R.","family":"Docherty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7694-6391","authenticated-orcid":false,"given":"Hang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2036-7603","authenticated-orcid":false,"given":"Vincent","family":"Koppelmans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4067-1859","authenticated-orcid":false,"given":"Joel","family":"Gelernter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0127-5455","authenticated-orcid":false,"given":"Anne K.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5137-9714","authenticated-orcid":false,"given":"Emily","family":"Hartwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"Dubroff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jon-Kar","family":"Zubieta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1018-0450","authenticated-orcid":false,"given":"Henry R.","family":"Kranzler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,11]]},"reference":[{"key":"1325_CR1","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1017\/S0033291711002145","volume":"42","author":"SS Martins","year":"2012","unstructured":"Martins SS, Fenton MC, Keyes KM, Blanco C, Zhu H, Storr CL. Mood and anxiety disorders and their association with non-medical prescription opioid use and prescription opioid-use disorder: longitudinal evidence from the National Epidemiologic Study on Alcohol and Related Conditions. Psychol Med. 2012;42:1261\u201372.","journal-title":"Psychol Med"},{"key":"1325_CR2","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.drugalcdep.2015.05.010","volume":"153","author":"DS Fink","year":"2015","unstructured":"Fink DS, Hu R, Cerd\u00e1 M, Keyes KM, Marshall BDL, Galea S, et al. Patterns of major depression and nonmedical use of prescription opioids in the United States. Drug Alcohol Depend. 2015;153:258\u201364.","journal-title":"Drug Alcohol Depend"},{"key":"1325_CR3","unstructured":"SAMHSA. Results from the 2019 national survey on drug use and health. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2020."},{"key":"1325_CR4","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1001\/jamapsychiatry.2020.3554","volume":"78","author":"DB Rosoff","year":"2021","unstructured":"Rosoff DB, Smith GD, Lohoff FW. Prescription opioid use and risk for major depressive disorder and anxiety and stress-related disorders: A multivariable Mendelian randomization analysis. JAMA Psychiatry. 2021;78:151\u201360.","journal-title":"JAMA Psychiatry."},{"key":"1325_CR5","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1001\/archpsyc.60.11.1145","volume":"60","author":"J-K Zubieta","year":"2003","unstructured":"Zubieta J-K, Ketter TA, Bueller JA, Xu Y, Kilbourn MR, Young EA, et al. Regulation of human affective responses by anterior cingulate and limbic mu-opioid neurotransmission. Arch Gen Psychiatry. 2003;60:1145\u201353.","journal-title":"Arch Gen Psychiatry"},{"key":"1325_CR6","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/s41380-018-0117-2","volume":"24","author":"M Peci\u00f1a","year":"2019","unstructured":"Peci\u00f1a M, Karp JF, Mathew S, Todtenkopf MS, Ehrich EW, Zubieta J-K. Endogenous opioid system dysregulation in depression: implications for new therapeutic approaches. Mol Psychiatry. 2019;24:576\u201387.","journal-title":"Mol Psychiatry"},{"key":"1325_CR7","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/0006-8993(95)00333-L","volume":"682","author":"AM Gabilondo","year":"1995","unstructured":"Gabilondo AM, Meana JJ, Garc\u00eda-Sevilla JA. Increased density of mu-opioid receptors in the postmortem brain of suicide victims. Brain Res. 1995;682:245\u201350.","journal-title":"Brain Res"},{"key":"1325_CR8","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1038\/sj.npp.1300459","volume":"29","author":"PV Escrib\u00e1","year":"2004","unstructured":"Escrib\u00e1 PV, Ozaita A, Garc\u00eda-Sevilla JA. Increased mRNA expression of alpha2A-adrenoceptors, serotonin receptors and mu-opioid receptors in the brains of suicide victims. Neuropsychopharmacology. 2004;29:1512\u201321.","journal-title":"Neuropsychopharmacology."},{"key":"1325_CR9","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/s41583-018-0028-x","volume":"19","author":"E Darcq","year":"2018","unstructured":"Darcq E, Kieffer BL. Opioid receptors: drivers to addiction? Nat Rev Neurosci. 2018;19:499\u2013514.","journal-title":"Nat Rev Neurosci"},{"key":"1325_CR10","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/s41593-018-0326-7","volume":"22","author":"DM Howard","year":"2019","unstructured":"Howard DM, Adams MJ, Clarke T-K, Hafferty JD, Gibson J, Shirali M, et al. Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions. Nat Neurosci. 2019;22:343\u201352.","journal-title":"Nat Neurosci"},{"key":"1325_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.copsyc.2018.07.014","volume":"27","author":"RC Crist","year":"2019","unstructured":"Crist RC, Reiner BC, Berrettini WH. A review of opioid addiction genetics. Curr Opin Psychol 2019;27:31\u201335.","journal-title":"Curr Opin Psychol"},{"key":"1325_CR12","doi-asserted-by":"publisher","unstructured":"Zhou H, Rentsch CT, Cheng Z, Kember RL, Nunez YZ, Sherva RM, et al. Association of OPRM1 functional coding variant with opioid use disorder: a genome-wide association study. JAMA Psychiatry. 2020. https:\/\/doi.org\/10.1001\/jamapsychiatry.2020.1206","DOI":"10.1001\/jamapsychiatry.2020.1206"},{"key":"1325_CR13","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.copsyc.2018.09.002","volume":"27","author":"JS Anderson","year":"2019","unstructured":"Anderson JS, Shade J, DiBlasi E, Shabalin AA, Docherty AR. Polygenic risk scoring and prediction of mental health outcomes. Curr Opin Psychol. 2019;27:77\u201381.","journal-title":"Curr Opin Psychol."},{"key":"1325_CR14","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s00429-014-0717-9","volume":"220","author":"E Erbs","year":"2015","unstructured":"Erbs E, Faget L, Scherrer G, Matifas A, Filliol D, Vonesch JL, et al. A mu-delta opioid receptor brain atlas reveals neuronal co-occurrence in subcortical networks. Brain Struct Funct. 2015;220:677\u2013702.","journal-title":"Brain Struct Funct"},{"key":"1325_CR15","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.neuropharm.2013.08.028","volume":"76 Pt B","author":"P Charbogne","year":"2014","unstructured":"Charbogne P, Kieffer BL, Befort K. 15 years of genetic approaches in vivo for addiction research: Opioid receptor and peptide gene knockout in mouse models of drug abuse. Neuropharmacology. 2014;76 Pt B:204\u201317.","journal-title":"Neuropharmacology."},{"key":"1325_CR16","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/mp.2014.185","volume":"20","author":"DT Hsu","year":"2015","unstructured":"Hsu DT, Sanford BJ, Meyers KK, Love TM, Hazlett KE, Walker SJ, et al. It still hurts: altered endogenous opioid activity in the brain during social rejection and acceptance in major depressive disorder. Mol Psychiatry. 2015;20:193\u2013200.","journal-title":"Mol Psychiatry"},{"key":"1325_CR17","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1073\/pnas.94.4.1544","volume":"94","author":"I Sora","year":"1997","unstructured":"Sora I, Takahashi N, Funada M, Ujike H, Revay RS, Donovan DM, et al. Opiate receptor knockout mice define mu receptor roles in endogenous nociceptive responses and morphine-induced analgesia. Proc Natl Acad Sci USA. 1997;94:1544\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1325_CR18","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1038\/383819a0","volume":"383","author":"HWD Matthes","year":"1996","unstructured":"Matthes HWD, Maldonado R, Simonin F, Valverde O, Slowe S, Kitchen I, et al. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature. 1996;383:819\u201323.","journal-title":"Nature."},{"key":"1325_CR19","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1017\/S146114571200017X","volume":"16","author":"EM Weerts","year":"2013","unstructured":"Weerts EM, McCaul ME, Kuwabara H, Yang X, Xu X, Dannals RF, et al. Influence of OPRM1 Asn40Asp variant (A118G) on [11C]carfentanil binding potential: preliminary findings in human subjects. Int J Neuropsychopharmacol. 2013;16:47\u201353.","journal-title":"Int J Neuropsychopharmacol"},{"key":"1325_CR20","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1038\/npp.2014.272","volume":"40","author":"M Peci\u00f1a","year":"2015","unstructured":"Peci\u00f1a M, Love T, Stohler CS, Goldman D, Zubieta J-K. Effects of the Mu opioid receptor polymorphism (OPRM1 A118G) on pain regulation, placebo effects and associated personality trait measures. Neuropsychopharmacology. 2015;40:957\u201365.","journal-title":"Neuropsychopharmacology."},{"key":"1325_CR21","doi-asserted-by":"publisher","first-page":"9268","DOI":"10.1073\/pnas.1018699108","volume":"108","author":"R Ray","year":"2011","unstructured":"Ray R, Ruparel K, Newberg A, Wileyto EP, Loughead JW, Divgi C, et al. Human Mu Opioid Receptor (OPRM1 A118G) polymorphism is associated with brain mu-opioid receptor binding potential in smokers. Proc Natl Acad Sci USA. 2011;108:9268\u201373.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1325_CR22","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1038\/nature06858","volume":"452","author":"Z Zhou","year":"2008","unstructured":"Zhou Z, Zhu G, Hariri AR, Enoch MA, Scott D, Sinha R, et al. Genetic variation in human NPY expression affects stress response and emotion. Nature. 2008;452:997\u20131001.","journal-title":"Nature."},{"key":"1325_CR23","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1126\/science.1060952","volume":"293","author":"JK Zubieta","year":"2001","unstructured":"Zubieta JK, Smith YR, Bueller JA, Xu Y, Kilbourn MR, Jewett DM, et al. Regional mu opioid receptor regulation of sensory and affective dimensions of pain. Science. 2001;293:311\u20135.","journal-title":"Science."},{"key":"1325_CR24","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1176\/ajp.156.6.842","volume":"156","author":"JK Zubieta","year":"1999","unstructured":"Zubieta JK, Dannals RF, Frost JJ. Gender and age influences on human brain mu-opioid receptor binding measured by PET. Am J Psychiatry. 1999;156:842\u20138.","journal-title":"Am J Psychiatry"},{"key":"1325_CR25","doi-asserted-by":"publisher","first-page":"5100","DOI":"10.1523\/JNEUROSCI.22-12-05100.2002","volume":"22","author":"J-K Zubieta","year":"2002","unstructured":"Zubieta J-K, Smith YR, Bueller JA, Xu Y, Kilbourn MR, Jewett DM, et al. mu-opioid receptor-mediated antinociceptive responses differ in men and women. J Neurosci. 2002;22:5100\u20137.","journal-title":"J Neurosci"},{"key":"1325_CR26","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1038\/ng.3097","volume":"46","author":"AR Wood","year":"2014","unstructured":"Wood AR, Esko T, Yang J, Vedantam S, Pers TH, Gustafsson S, et al. Defining the role of common variation in the genomic and biological architecture of adult human height. Nat Genet. 2014;46:1173\u201386.","journal-title":"Nat Genet"},{"key":"1325_CR27","doi-asserted-by":"publisher","first-page":"7754","DOI":"10.1523\/JNEUROSCI.0439-05.2005","volume":"25","author":"J-K Zubieta","year":"2005","unstructured":"Zubieta J-K. Placebo effects mediated by endogenous opioid activity on mu-opioid receptors. J Neurosci. 2005;25:7754\u201362.","journal-title":"J Neurosci"},{"key":"1325_CR28","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1001\/jamapsychiatry.2015.1335","volume":"72","author":"M Peci\u00f1a","year":"2015","unstructured":"Peci\u00f1a M, Bohnert ASB, Sikora M, Avery ET, Langenecker SA, Mickey BJ, et al. Association between placebo-activated neural systems and antidepressant responses: neurochemistry of placebo effects in major depression. JAMA Psychiatry. 2015;72:1087\u201394.","journal-title":"JAMA Psychiatry."},{"key":"1325_CR29","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1126\/science.1078546","volume":"299","author":"J-K Zubieta","year":"2003","unstructured":"Zubieta J-K, Heitzeg MM, Smith YR, Bueller JA, Xu K, Xu Y, et al. COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science. 2003;299:1240\u20133.","journal-title":"Science."},{"key":"1325_CR30","doi-asserted-by":"publisher","first-page":"14729","DOI":"10.1523\/JNEUROSCI.1400-13.2013","volume":"33","author":"IK Martikainen","year":"2013","unstructured":"Martikainen IK, Pecina M, Love TM, Nuechterlein EB, Cummiford CM, Green CR, et al. Alterations in endogenous opioid functional measures in chronic back pain. J Neurosci. 2013;33:14729\u201337.","journal-title":"J Neurosci"},{"key":"1325_CR31","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/nature15393","volume":"526","author":"AA Auton","year":"2015","unstructured":"1000 Genomes Project Consortium, Auton AA, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, et al. A global reference for human genetic variation. Nature. 2015;526:68\u201374.","journal-title":"Nature."},{"key":"1325_CR32","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0304-3959(98)00171-7","volume":"79","author":"CS Stohler","year":"1999","unstructured":"Stohler CS, Kowalski CJ. Spatial and temporal summation of sensory and affective dimensions of deep somatic pain. Pain. 1999;79:165\u201373.","journal-title":"Pain."},{"key":"1325_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09718-5","volume":"10","author":"T Ge","year":"2019","unstructured":"Ge T, Chen C-Y, Ni Y, Feng Y-CA, Smoller JW. Polygenic prediction via Bayesian regression and continuous shrinkage priors. Nat Commun. 2019;10:1776.","journal-title":"Nat Commun"},{"key":"1325_CR34","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc. 1995;57:289\u2013300.","journal-title":"J R Stat Soc"},{"key":"1325_CR35","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1523\/JNEUROSCI.4205-06.2007","volume":"27","author":"KS Smith","year":"2007","unstructured":"Smith KS, Berridge KC. Opioid limbic circuit for reward: interaction between hedonic hotspots of nucleus accumbens and ventral pallidum. J Neurosci. 2007;27:1594\u2013605.","journal-title":"J Neurosci"},{"key":"1325_CR36","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1176\/appi.ajp.162.8.1403","volume":"162","author":"PW Kalivas","year":"2005","unstructured":"Kalivas PW, Volkow ND. The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry. 2005;162:1403\u201313.","journal-title":"Am J Psychiatry"},{"key":"1325_CR37","doi-asserted-by":"crossref","unstructured":"Berridge KC, Kringelbach ML. Towards a neuroscience of well-being: implications of insights from pleasure research. In: Happiness studies book series. Springer Netherlands; 2013. p. 81\u2013100.","DOI":"10.1007\/978-94-007-6609-9_7"},{"key":"1325_CR38","doi-asserted-by":"publisher","first-page":"430","DOI":"10.3389\/fnbeh.2014.00430","volume":"8","author":"GE Loseth","year":"2014","unstructured":"Loseth GE, Ellingsen D-M, Leknes S. State-dependent \u03bc-opioid modulation of social motivation. Front Behav Neurosci. 2014;8:430.","journal-title":"Front Behav Neurosci"},{"key":"1325_CR39","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/mp.2013.96","volume":"18","author":"DT Hsu","year":"2013","unstructured":"Hsu DT, Sanford BJ, Meyers KK, Love TM, Hazlett KE, Wang H, et al. Response of the \u03bc-opioid system to social rejection and acceptance. Mol Psychiatry. 2013;18:1211\u20137.","journal-title":"Mol Psychiatry"},{"key":"1325_CR40","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S2215-0366(16)00104-8","volume":"3","author":"GF Koob","year":"2016","unstructured":"Koob GF, Volkow ND. Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry. 2016;3:760\u201373.","journal-title":"Lancet Psychiatry."},{"key":"1325_CR41","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.neuron.2011.01.027","volume":"69","author":"ND Volkow","year":"2011","unstructured":"Volkow ND, Baler RD, Goldstein RZ. Addiction: pulling at the neural threads of social behaviors. Neuron. 2011;69:599\u2013602.","journal-title":"Neuron."},{"key":"1325_CR42","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1001\/archgenpsychiatry.2009.134","volume":"66","author":"TM Love","year":"2009","unstructured":"Love TM, Stohler CS, Zubieta J-K. Positron emission tomography measures of endogenous opioid neurotransmission and impulsiveness traits in humans. Arch Gen Psychiatry. 2009;66:1124\u201334.","journal-title":"Arch Gen Psychiatry"},{"key":"1325_CR43","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1037\/bul0000102","volume":"143","author":"RH Salk","year":"2017","unstructured":"Salk RH, Hyde JS, Abramson LY. Gender differences in depression in representative national samples: Meta-analyses of diagnoses and symptoms. Psychol Bull. 2017;143:783\u2013822.","journal-title":"Psychol Bull"},{"key":"1325_CR44","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.jpain.2009.07.016","volume":"11","author":"RN Jamison","year":"2010","unstructured":"Jamison RN, Butler SF, Budman SH, Edwards RR, Wasan AD. Gender differences in risk factors for aberrant prescription opioid use. J Pain. 2010;11:312\u201320.","journal-title":"J Pain"},{"key":"1325_CR45","doi-asserted-by":"publisher","first-page":"106149","DOI":"10.1016\/j.addbeh.2019.106149","volume":"102","author":"EA Evans","year":"2020","unstructured":"Evans EA, Goff SL, Upchurch DM, Grella CE. Childhood adversity and mental health comorbidity in men and women with opioid use disorders. Addict Behav. 2020;102:106149.","journal-title":"Addict Behav"},{"key":"1325_CR46","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.addbeh.2009.01.002","volume":"34","author":"CE Grella","year":"2009","unstructured":"Grella CE, Karno MP, Warda US, Niv N, Moore AA. Gender and comorbidity among individuals with opioid use disorders in the NESARC study. Addict Behav. 2009;34:498\u2013504.","journal-title":"Addict Behav"},{"key":"1325_CR47","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jsat.2012.12.007","volume":"45","author":"RK McHugh","year":"2013","unstructured":"McHugh RK, Devito EE, Dodd D, Carroll KM, Potter JS, Greenfield SF, et al. Gender differences in a clinical trial for prescription opioid dependence. J Subst Abus Treat. 2013;45:38\u201343.","journal-title":"J Subst Abus Treat"},{"key":"1325_CR48","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3109\/00952990.2011.596982","volume":"37","author":"SE Back","year":"2011","unstructured":"Back SE, Payne RL, Wahlquist AH, Carter RE, Stroud Z, Haynes L, et al. Comparative profiles of men and women with opioid dependence: results from a national multisite effectiveness trial. Am J Drug Alcohol Abus. 2011;37:313\u201323.","journal-title":"Am J Drug Alcohol Abus"},{"key":"1325_CR49","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.drugalcdep.2004.02.001","volume":"74","author":"CA Hernandez-Avila","year":"2004","unstructured":"Hernandez-Avila CA, Rounsaville BJ, Kranzler HR. Opioid-, cannabis- and alcohol-dependent women show more rapid progression to substance abuse treatment. Drug Alcohol Depend. 2004;74:265\u201372.","journal-title":"Drug Alcohol Depend"},{"key":"1325_CR50","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1001\/archpsyc.63.11.1199","volume":"63","author":"SE Kennedy","year":"2006","unstructured":"Kennedy SE, Koeppe RA, Young EA, Zubieta J-K. Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women. Arch Gen Psychiatry. 2006;63:1199\u2013208.","journal-title":"Arch Gen Psychiatry"},{"key":"1325_CR51","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1038\/s41386-018-0225-3","volume":"43","author":"RJ Valentino","year":"2018","unstructured":"Valentino RJ, Volkow ND. Untangling the complexity of opioid receptor function. Neuropsychopharmacology. 2018;43:2514\u201320.","journal-title":"Neuropsychopharmacology."}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41386-022-01325-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-022-01325-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-022-01325-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T10:45:58Z","timestamp":1727174758000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41386-022-01325-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,11]]},"references-count":51,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["1325"],"URL":"https:\/\/doi.org\/10.1038\/s41386-022-01325-1","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"type":"print","value":"0893-133X"},{"type":"electronic","value":"1740-634X"}],"subject":[],"published":{"date-parts":[[2022,5,11]]},"assertion":[{"value":"31 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"HRK is a scientific advisory board member for Dicerna Pharmaceuticals, Sophrosyne Pharmaceuticals, and Enthion Pharmaceuticals; a consultant for Sobrera Pharmaceuticals; the recipient of research funding and medication supplies for an investigator-initiated study from Alkermes; and a member of the American Society of Clinical Psychopharmacology\u2019s Alcohol Clinical Trials Initiative (ACTIVE Group), which over the past three years was supported by Alkermes, Dicerna, Ethypharm, Lundbeck, Mitsubishi, and Otsuka. HRK and JG hold US patent 10,900,082\u00a0titled: \u201cGenotype-guided dosing of opioid agonists,\u201d 26 Jan. 2021. The other authors have no interests to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}